42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Public ClinicalTrials.gov record NCT01381094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4
Study identification
- NCT ID
- NCT01381094
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Akebia Therapeutics
- Industry
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Interventions
- AKB-6548 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2011
- Primary completion
- Feb 15, 2012
- Completion
- Feb 15, 2012
- Last update posted
- Jun 30, 2022
2011 – 2012
United States locations
- U.S. sites
- 28
- U.S. states
- 13
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Pine Bluff | Arkansas | — | — |
| Not listed | Covina | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Lynwood | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | San Dimas | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Coral Springs | Florida | — | — |
| Not listed | Lauderdale Lakes | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Macon | Georgia | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Springfield | Massachusetts | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Pontiac | Michigan | — | — |
| Not listed | Warren | Michigan | — | — |
| Not listed | Bethpage | New York | — | — |
| Not listed | Mineola | New York | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01381094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2022 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01381094 live on ClinicalTrials.gov.